Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

Nature

Volumn 438, Issue 7064, 2005, Pages 99-102

  Veazey, Ronald S ^a   Klasse, Per Johan ^b   Schader, Susan M ^b   Hu, Qinxue ^c   Ketas, Thomas J ^b   Lu, Min ^b   Marx, Preston A ^a   Dufour, Jason ^a   Colonno, Richard J ^d   Shattock, Robin J ^c   Springer, Martin S ^e   Moore, John P ^b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; EDUCATION; IMMUNOLOGY; PLANTS (BOTANY); PROTEINS; TISSUE;

BEHAVIORAL-MODIFICATION PROGRAMMES; HETEROSEXUAL SEX; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1);

VIRUSES;

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C 52 L; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CMPD 167; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

HUMAN IMMUNODEFICIENCY VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM; CELL ADHESION; CELL FUSION; CELL LINE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RHESUS MONKEY; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VAGINA; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS TRANSMISSION;

ANIMALIA; BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 27744571425     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04055     Document Type: Article

References (30)

1. Klausner, R. D. et al. Medicine. The need for a global HIV vaccine enterprise. Science 300, 2036-2069 (2003).
2. Shattock, R. A. & Moore, J. P. Inhibiting HIV-1 sexual transmission. Nature Rev. Microbiol. 1, 25-34 (2003).
3. Lin, P. F. et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl Acad. Sci. USA 100, 11013-11018 (2003).
4. Guo, Q. et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 77, 10528-10536 (2003).
5. Shen, D. M. et al. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds. Bioorg. Med. Chem. Lett. 14, 941-945 (2004).
6. Lu, M. Stabilizing peptides and their use in the preparation of stabilized HIV inhibitors. World Intellectual Property Organization Patent WO-04/106364A1 (2004).
7. Seibert, C. & Sakmar, T. P. Small-molecule antagonists of CCR5 and CXCR4: A promising new class of anti-HIV-1 drugs. Curr. Pharmacol. Des. 10, 2041-2062 (2004).
8. Veazey, R. S. et al. Use of a small-molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection and prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198, 1551-1562 (2003).
9. Wolinsky, S. M. et al. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 328, 19-29 (2004).
10. Hanna, G. et al. Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. Abstr. 141, 11th Conf. Retroviruses Opportunistic Infect. 〈http://www.retroconference.org/Search_Abstract_2004/AbstractSearch. aspx〉 (2004).
11. Matthews, T. et al. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nature Rev. Drug Disc. 3, 215-221 (2004).
12. SF162P3. J. Virol. 75, 1990-1995 (2001).
13. Moore, J. P., Kitchen, S. G., Pugach, P. & Zack, J. A. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20, 111-126 (2004).
14. Veazey, R. S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature Med. 9, 343-346 (2003).
15. Lederman, M. M. et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306, 485-487 (2004).
16. Tsai, C. C. et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 20, 11-18 (2004).
17. Hu, Q. et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J. Exp. Med. 199, 1065-1075 (2004).
18. Tremblay, C. Effects of HIV-1 entry inhibitors in combination. Curr. Pharm. Des. 10, 1861-1865 (2004).
19. Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T. P. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol. Pharmacol. 67, 1268-1282 (2005).
20. Sparks, S. et al. Prolonged duration of CCR5 occupancy by 873140 in HIV-negative and HIV-positive subjects. Abstr. 77, 12th Conf. Retroviruses Opportunistic Infect. 〈http://www.retroconference.org/Search_Abstract_2005/ AbstractSearch.aspx〉 (2005).
21. Marx, P. A. et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nature Med. 2, 1084-1089 (1996).
22. Otten, R. A. et al. Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J. Infect. Dis. 191, 164-173 (2005).
23. Dyer, J. R. et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J. Infect. Dis. 177, 1742-1746 (1998).
24. Wawer, M. J. et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191, 1403-1409 (2005).
25. Reeves, J. D. et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl Acad. Sci. USA 99, 16249-16254 (2002).
26. Miller, C. J. et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79, 9217-9227 (2005).
27. Pope, M. & Haase, A. T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nature Med. 9, 847-852 (2003).
28. Ketas, T. J. et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res. Hum. Retroviruses 19, 177-186 (2003).
29. Wang, T. et al. Discovery of 4-Benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b] pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 46, 4236-4239 (2003).
30. Ji, H., Bracken, C. & Lu, M. Buried polar interactions and conformational stability in the simian immunodeficiency virus (SIV) gp41 core. Biochemistry 39, 676-685 (2000).